A Cell Cycle Progression-Derived Gene Signature to Predict Prognosis and Therapeutic Response in Hepatocellular Carcinoma

Figure 8

CCP-derived gene signature acts as a reliable prognostic indicator independent of genetic mutation. (a) Landscape of somatic mutation of HCC specimens. (b–i) Survival analysis of high- and low-risk HCC patients in each subgroup (TP53 mutation and nonmutation subgroups; CTNNB1 mutation and nonmutation subgroups, TTN mutation and nonmutation subgroups, and MUC16 mutation and nonmutation subgroups).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)